The head of the Gamalia Center, Alexander Gintsburg, said that the first use of the Russian personalized cancer vaccine was successful. The first patient stopped developing new metastases. It will now be kept for 3 years to see how the vaccine performs in the long term. If all goes well, this will be a very serious breakthrough for our medicine. It is clarified that this is not a universal vaccine, but is developed for each specific patient.